Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Å. Nilsson. (2006) Optimizing management of distal ulcerative colitis. Scandinavian Journal of Gastroenterology 41:5, pages 511-523.
Read now
Read now
Guy Van den Mooter & Renaat Kinget. (1995) Oral colon-specific drug delivery: a review. Drug Delivery 2:2, pages 81-93.
Read now
Read now
M. C. M. Rijk, A. vanSchaik & J. H. M. Van Tongeren. (1992) Disposition of Mesalazine from Mesalazine-Delivering Drugs in Patients with Inflammatory Bowel Disease, with and without Diarrhoea. Scandinavian Journal of Gastroenterology 27:10, pages 863-868.
Read now
Read now
M. Ryde, H. Sandberg-gertzén, G. Järnerot, K. Lauritsen, J. Rask-Madsen & N.-O. Ahnfelt. (1988) Is 5-Aminosalicylic Acid Delivered Directly to the Colon by Olsalazine?. Scandinavian Journal of Gastroenterology 23:sup148, pages 104-106.
Read now
Read now
A. Ireland & D. P. Jewell. (1988) Olsalazine in Patients Intolerant of Sulphasalazine. Scandinavian Journal of Gastroenterology 23:sup148, pages 101-103.
Read now
Read now
D. J. Hetzel, D. J. C. Shearman, J. Labrooy, F. Bochner, D. M. Imhoff, G. E. Gibson, R. J. Fitch, R. Hecker & R. Rowland. (1988) Olsalazine in the Treatment of Active Ulcerative Colitis: A Placebo Controlled Clinical Trial and Assessment of Drug Disposition. Scandinavian Journal of Gastroenterology 23:sup148, pages 61-69.
Read now
Read now
H. Sandberg-gertzén, G. Järnerot & C. Tysk. (1988) Long-Term Treatment with Olsalazine for Ulcerative Colitis:Safety and Relapse Prevention:AFollow-upStudy. Scandinavian Journal of Gastroenterology 23:sup148, pages 48-50.
Read now
Read now
S. Meyers, D. B. Sachar, D. H. Present & H. D. Janowitz. (1988) Olsalazine in the Treatment of Ulcerative Colitis among Patients Intolerant of Sulphasalazine: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Clinical Trial. Scandinavian Journal of Gastroenterology 23:sup148, pages 29-37.
Read now
Read now
T. Berglindh, E. Landström & E. Bergqvist. (1988) Induction of and Adaptation to Olsalazine Induced Intestinal Volume Load. Scandinavian Journal of Gastroenterology 23:sup148, pages 24-28.
Read now
Read now
G. Järnerot. (1988) Clinical Tolerance of Olsalazine. Scandinavian Journal of Gastroenterology 23:sup148, pages 21-23.
Read now
Read now
R. A. Van Hogezand. (1988) Pharmacokinetics of Olsalazine and Its Metabolites. Scandinavian Journal of Gastroenterology 23:sup148, pages 17-20.
Read now
Read now
D. E. S. Campbell & T. Berglindh. (1988) Pharmacology of Olsalazine. Scandinavian Journal of Gastroenterology 23:sup148, pages 7-12.
Read now
Read now
G. Järnerot, H. Sandberg-Gertzén, P. Tobiasson & K. J. Vikterlöf. (1988) Olsalazine Does Not Increase the Bile Acid Losses in Subjects with a Permanent Ileostomy. Scandinavian Journal of Gastroenterology 23:4, pages 489-492.
Read now
Read now
A. Ireland & D. P. Jewell. (1987) Olsalazine in Patients Intolerant of Sulphasalazine. Scandinavian Journal of Gastroenterology 22:9, pages 1038-1040.
Read now
Read now
H. Sandberg Gertzen, J. Kjellander, B. Sundberg-Gillar & G. Jarrnerot. (1985) In Vitro Effects of Sulphasalazine, Azodisal Sodium, and Their Metabolites on Clostridium difficile and Some Other Faecal Bacteria. Scandinavian Journal of Gastroenterology 20:5, pages 607-612.
Read now
Read now
H. Sandberg-Gertzén, M. Ryde & G. Järnerot. (1983) Absorption and Excretion of Azodisal Sodium and Its Metabolites in Man after Rectal Administration of a Single 2-g Dose. Scandinavian Journal of Gastroenterology 18:4, pages 571-575.
Read now
Read now
Articles from other publishers (40)
Femke Crouwel, Hans J C Buiter & Nanne K de Boer. (2021) Gut Microbiota-driven Drug Metabolism in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 15:2, pages 307-315.
Crossref
Crossref
Jagadeesh Banda, Ramalingam Lakshmanan, Ramesh Babu Katepalli, Uday Kumar Reddy Venati, Ramesh Koppula & V.V.S. Shiva Prasad. (2016) Determination of mesalazine, a low bioavailability olsalazine metabolite in human plasma by UHPLC–MS/MS: Application to a pharmacokinetic study. Journal of Chromatography B 1008, pages 1-10.
Crossref
Crossref
M. P. THORPE, E. D. EHRENPREIS, K. S. PUTT & B. HANNON. (2009) A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol). Alimentary Pharmacology & Therapeutics 29:11, pages 1193-1201.
Crossref
Crossref
U. Klotz. (2005) Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Digestive and Liver Disease 37:6, pages 381-388.
Crossref
Crossref
N. Mahmud, D. O'Toole, N. O'Hare, P. J. Freyne, D. G. Weir & D. Kelleher. (2002) Evaluation of renal function following treatment with 5‐aminosalicylic acid derivatives in patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics 16:2, pages 207-215.
Crossref
Crossref
Robert B. Stein & Stephen B. Hanauer. (2000) Comparative Tolerability of Treatments for Inflammatory Bowel Disease. Drug Safety 23:5, pages 429-448.
Crossref
Crossref
N. Mahmud, D. G. Weir & D. Kelleher. (1999) Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. Irish Journal of Medical Science 168:4, pages 228-232.
Crossref
Crossref
Stig Bondesen. (1997) INTESTINAL FATE OF 5-AMINOSALICYLIC ACID: REGIONAL AND SYSTEMIC KINETIC STUDIES IN RELATION TO INFLAMMATORY BOWEL DISEASE. Pharmacology & Toxicology 81, pages 1-30.
Crossref
Crossref
James A. MartensonJr.Jr., Glenn Hyland, Charles G. Moertel, James A. Mailliard, Judith R. O'Fallon, Roger T. Collins, Roscoe F. Morton, Hamed H. Tewfik, Randy L. Moore, Albert R. Frank, Rodolfo E. Urias & Richard L. Deming. (1996) Olsalazine is contraindicated during pelvic radiation therapy: Results of a double-blind, randomized clinical trial. International Journal of Radiation Oncology*Biology*Physics 35:2, pages 299-303.
Crossref
Crossref
Anupama Chawla, Peter I. Karl, Rosandra N. Reich, Gopal Narasimhan, Gregory A. Michaud, Stanley E. Fisher & Benjamin L. Schneider. (1995) Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Digestive Diseases and Sciences 40:5, pages 943-948.
Crossref
Crossref
J. P. Wright, D. P. Jewell, R. Modigliani & H. Malchow. (1995) A Randomized, Double-Blind, Placebo-Controlled Trial of Olsalazine for Active Crohnʼs Disease. Inflammatory Bowel Diseases 1:4, pages 241-246.
Crossref
Crossref
Douglas S. Levine. 1994.
171
234
.
S.P.L. Travis & D.P. Jewell. (1994) Salicylates for ulcerative colitis—their mode of action. Pharmacology & Therapeutics 63:2, pages 135-161.
Crossref
Crossref
G. F. Bonner & W. B. Ruderman. (1993) 5-aminosalicylic acid preparations in the treatment of inflammatory bowel disease. Inflammopharmacology 2:3, pages 247-262.
Crossref
Crossref
B Crotty & DP Jewell. (2012) Drug therapy of ulcerative colitis.. British Journal of Clinical Pharmacology 34:3, pages 189-198.
Crossref
Crossref
M.G. Courtney, D.P. Nunes, C.F. Bergin, M. O'Driscoll, V. Trimble, P.W.N. Keeling & D.G. Weir. (1992) Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. The Lancet 339:8804, pages 1279-1281.
Crossref
Crossref
M. H. GIAFFER, C. J. O'BRIEN & C. D. HOLDSWORTH. (2007) Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Alimentary Pharmacology & Therapeutics 6:1, pages 51-59.
Crossref
Crossref
David R. Friend. (1991) Colon-specific drug delivery. Advanced Drug Delivery Reviews 7:1, pages 149-199.
Crossref
Crossref
M. Ryde, B. Huitfeldt & R. Pettersson. (2006) Relative bioavailability of olsalazine from tablets and capsules: A drug targeted for local effect in the colon. Biopharmaceutics & Drug Disposition 12:3, pages 233-246.
Crossref
Crossref
A H Raimundo, D H Patil, P G Frost & D B Silk. (1991) Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.. Gut 32:3, pages 270-274.
Crossref
Crossref
David R. Friend, Sandra Phillips & Thomas N. Tozer. (1991) Colon-specific drug delivery from a glucoside prodrug in the guinea-pig. Efficacy study. Journal of Controlled Release 15:1, pages 47-54.
Crossref
Crossref
L Staerk Laursen, M Stokholm, K Bukhave, J Rask-Madsen & K Lauritsen. (1990) Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.. Gut 31:11, pages 1271-1276.
Crossref
Crossref
L. A. CHRISTENSEN, J. FALLINGBORG, K. ABILDGAARD, B. A. JACOBSEN, G. SANCHEZ, S. H. HANSEN, S. BONDESEN, E. F. HVIDBERG & S. NØRBY RASMUSSEN. (2007) Topical and systemic availability of 5-amino-salicylate: comparisons of three controlled release preparations in man. Alimentary Pharmacology & Therapeutics 4:5, pages 523-533.
Crossref
Crossref
Stephen B. Hanauer. 1990. Inflammatory Bowel Diseases 1990. Inflammatory Bowel Diseases 1990
167
177
.
G E Feurle, D Theuer, S Velasco, B A Barry, D Wordehoff, A Sommer, G Jantschek & W Kruis. (1989) Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.. Gut 30:10, pages 1354-1361.
Crossref
Crossref
Rifat Pamukcu, Stephen B. Hanauer & Eugene B. Chang. (1988) Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Gastroenterology 95:4, pages 975-981.
Crossref
Crossref
R. A. van Hogezand, A. van Schaik, P. A. M. van Hees & J. H. M. van Tongeren. (1988) Stability of disodium azodisalicylate (olsalazine) and metabolites in urine and faeces stored at different temperatures. European Journal of Drug Metabolism and Pharmacokinetics 13:4, pages 261-265.
Crossref
Crossref
SA Riley, IA Tavares, A Bennett & V Mani. (2012) Delayed‐release mesalazine (5‐aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.. British Journal of Clinical Pharmacology 26:2, pages 173-177.
Crossref
Crossref
K Lauritsen, L Staerk Laursen, K Bukhave & J Rask-Madsen. (1988) Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.. Gut 29:7, pages 974-982.
Crossref
Crossref
K J Goerg, R Wanitschke, P H Diehl & K H Meyer zum Buschenfelde. (1988) Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro.. Gut 29:3, pages 336-341.
Crossref
Crossref
E. M. Ryde & N. -O. Ahnfelt. (1988) The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. European Journal of Clinical Pharmacology 34:5, pages 481-488.
Crossref
Crossref
K. Ewe. 1988. 94. Kongreß. 94. Kongreß
178
184
.
Samuel Meyers, David B. Sachar, Daniel H. Present & Henry D. Janowitz. (1987) Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. Gastroenterology 93:6, pages 1255-1262.
Crossref
Crossref
STIG BONDESEN, STEN NØRBY RASMUSSEN, JØRGEN RASK‐MADSEN, OLE HAAGEN NIELSEN, KARSTEN LAURITSEN, VIBEKE BINDER, STEEN HONORÉ HANSEN & EIGILL F. HVIDBERG. (2009) 5‐Aminosalicylic Acid in the Treatment of Inflammatory Bowel Disease. Acta Medica Scandinavica 221:3, pages 227-242.
Crossref
Crossref
H Sandberg-Gertzen, G Jarnerot, K Bukhave, K Lauritsen & J Rask-Madsen. (1986) Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.. Gut 27:11, pages 1306-1311.
Crossref
Crossref
D. J. HETZEL, D. J. C. SHEARMAN, F. BOCHNER, D. M. IMHOFF, G. E. GIBSON, R. J. FITCH, R. HECKER, J. LABROOY & R. ROWLAND. (2008) Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Journal of Gastroenterology and Hepatology 1:3, pages 257-266.
Crossref
Crossref
Hanna Sandberg-Gertzén, Gunnar Järnerot & Wolfgang Kraaz. (1986) Azodisal sodium in the treatment of ulcerative colitis. Gastroenterology 90:4, pages 1024-1030.
Crossref
Crossref
Gunnar JÄrnerot. 1986. Inflammatory Bowel Diseases 1986. Inflammatory Bowel Diseases 1986
213
223
.
R.A. van Hogezand, P.A.M. van Hees, B. Zwanenburg, J.M. van Rossum & J.H.M. van Tongeren. (1985) Disposition of disodium azodisalicylate in healthy subjects. Gastroenterology 88:3, pages 717-722.
Crossref
Crossref
Karsten Lauritsen, Jeppe Hansen, Marta Ryde & Jørgen Rask-Madsen. (1984) Colonic Azodisalicylate Metabolism Determined by In Vivo Dialysis in Healthy Volunteers and Patients With Ulcerative Colitis. Gastroenterology 86:6, pages 1496-1500.
Crossref
Crossref